These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27282892)

  • 1. Stent Coating Integrity of Durable and Biodegradable Coated Drug Eluting Stents.
    Yazdani SK; Sheehy A; Pacetti S; Rittlemeyer B; Kolodgie FD; Virmani R
    J Interv Cardiol; 2016 Oct; 29(5):483-490. PubMed ID: 27282892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Thrombogenicity of a Durable Polymer Everolimus-Eluting Stent Relative to Contemporary Drug-Eluting Stents With Biodegradable Polymer Coatings Assessed Ex Vivo in a Swine Shunt Model.
    Otsuka F; Cheng Q; Yahagi K; Acampado E; Sheehy A; Yazdani SK; Sakakura K; Euller K; Perkins LEL; Kolodgie FD; Virmani R; Joner M
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1248-1260. PubMed ID: 26292590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of drug eluting stent biocompatibility between third generation NOBORI biolimus A9-eluting stent and second generation XIENCE V everolimus-eluting stent in a porcine coronary artery model.
    Sumida A; Gogas BD; Nagai H; Li J; King SB; Chronos N; Hou D
    Cardiovasc Revasc Med; 2015 Sep; 16(6):351-7. PubMed ID: 26294337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolute and Xience V polymer-based drug-eluting stents compared in an atherosclerotic rabbit double injury model.
    Van Dyck CJ; Hoymans VY; Bult H; Fransen E; Haine S; Bosmans JM; Timmermans JP; Vrints CJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):E259-68. PubMed ID: 22887820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrity of stent polymer layer after drug-eluting stent implantation: in vivo comparison of sirolimus-, paclitaxel-, zotarolimus- and everolimus-eluting stents.
    Watanabe T; Fujita M; Awata M; Iida O; Okamoto S; Ishihara T; Uematsu M
    Cardiovasc Interv Ther; 2014 Jan; 29(1):4-10. PubMed ID: 23818255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries.
    Torii S; Nakazawa G; Ijichi T; Yoshikawa A; Ohno Y; Ikari Y
    Cardiovasc Interv Ther; 2018 Jan; 33(1):55-61. PubMed ID: 27822890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis.
    Kang SH; Park KW; Kang DY; Lim WH; Park KT; Han JK; Kang HJ; Koo BK; Oh BH; Park YB; Kandzari DE; Cohen DJ; Hwang SS; Kim HS
    Eur Heart J; 2014 May; 35(17):1147-58. PubMed ID: 24459196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year vascular responses to drug-eluting stents with biodegradable polymer versus durable polymer: An optical coherence tomography sub-study of the NEXT.
    Katayama Y; Kubo T; Akasaka T; Ino Y; Kimura K; Okura H; Shinke T; Igarashi K; Kadota K; Kozuma K; Tanabe K; Nakagawa Y; Muramatsu T; Morino Y; Kimura T;
    J Cardiol; 2017 Dec; 70(6):530-536. PubMed ID: 28536015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
    J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term vascular responses to Resolute® and Xience V® polymer-based drug-eluting stents in a rabbit model of atherosclerosis.
    Hoymans VY; VAN Dyck CJ; Haine SE; Frederix G; Fransen E; Timmermans JP; Vrints CJ
    J Interv Cardiol; 2014 Aug; 27(4):381-90. PubMed ID: 24815761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review.
    Ahmed TA; Bergheanu SC; Stijnen T; Plevier JW; Quax PH; Jukema JW
    EuroIntervention; 2011 Aug; 7(4):505-16. PubMed ID: 21764670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent.
    Toledano Delgado FJ; Alvarez-Ossorio MP; de Lezo Cruz-Conde JS; Bellido FM; Romero Moreno MÁ; Fernández-Aceytuno AM; de Lezo Herrerosde Tejada JS; Pineda SO; Saint-Gerons JM; Pavlovic D
    Catheter Cardiovasc Interv; 2014 Nov; 84(5):720-6. PubMed ID: 24174291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents.
    Yazdani SK; Sheehy A; Nakano M; Nakazawa G; Vorpahl M; Otsuka F; Donn RS; Perkins LE; Simonton CA; Kolodgie FD; Virmani R
    J Invasive Cardiol; 2013 Aug; 25(8):383-90. PubMed ID: 23913602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Late-Acquired Incomplete Stent Apposition: A Comparison With First-Generation and Second-Generation Drug-Eluting Stents.
    Waseda K; Ako J; Kume T; Fitzgerald PJ; Honda Y
    J Invasive Cardiol; 2016 Aug; 28(8):323-9. PubMed ID: 26689416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.